A

AnaptysBio
D

ANAB

14.520
USD
-0.05
(-0.34%)
مفتوح الان
حجم التداول
6,891
الربح لكل سهم
-6
العائد الربحي
-
P/E
-2
حجم السوق
441,824,463
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.030
    (-0.18%)
    16.850 USD
    ALNY
    ALNY
    -7.535
    (-3.07%)
    237.970 USD
    C
    CRSP
    -0.520
    (-1.28%)
    40.200 USD
    E
    ESPR
    0.05500
    (2.52%)
    2.23500 USD
    N
    NBIX
    -0.730
    (-0.54%)
    134.730 USD
    REGN
    REGN
    5.80
    (0.83%)
    708.40 USD
    S
    SRPT
    0.340
    (0.29%)
    119.310 USD
    V
    VKTX
    -0.640
    (-1.51%)
    41.630 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار
المقالات

العنوان: AnaptysBio

القطاع: Healthcare
الصناعة: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).